All Updates

All Updates

icon
Filter
Funding
OverT Bio emerges from stealth with USD 16 million in seed funding
Cell & Gene Therapy
May 6, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Cell & Gene Therapy

Cell & Gene Therapy

May 6, 2024

OverT Bio emerges from stealth with USD 16 million in seed funding

Funding

  • Cancer-focused cell therapy company OverT Bio emerged from stealth with USD 16 million in seed financing co-led by ARTIS Ventures and Wing VC. Other investors included Fusion Fund, OMX Ventures, and Alexandria Venture Investments, among others.

  • The proceeds will be channeled toward enhancing discovery platforms, focusing specifically on developing novel cell therapies targeting advanced solid tumors.

  • OverT Bio specializes in the development of cellular therapies for the treatment of solid tumors by leveraging pooled functional screening and synthetic genomics platforms named OverTarget and OverTune. These platforms facilitate the creation of next-generation engineered immune cells, aiming to advance the field of immunotherapy for cancer treatment​. Its approach entails researching the whole human genome to enhance the longevity and ability of cell therapies in eradicating cancers. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.